Clinical characteristics and outcomes for pregnant women diagnosed with COVID-19 disease at the University of Benin Teaching Hospital, Benin City, Nigeria

James Osaikhuwuomwan, Michael Ezeanochie, Charles Uwagboe, Kingsley Ndukwu, Sofiat Yusuf, Adedapo Ande

Corresponding author: Adedapo Ande, Materno-Foetal Unit, University of Benin Teaching Hospital, Benin City, Edo State, Nigeria. tundeande@gmail.com

Received: 30 Dec 2020 - Accepted: 07 Jan 2021 - Published: 16 Jun 2021

Keywords: COVID-19, coronavirus, pregnancy, Nigeria

Copyright: James Osaikhuwuomwan et al. Pan African Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cite this article: James Osaikhuwuomwan et al. Clinical characteristics and outcomes for pregnant women diagnosed with COVID-19 disease at the University of Benin Teaching Hospital, Benin City, Nigeria. Pan African Medical Journal. 2021;39(134). 10.11604/pamj.2021.39.134.27627

Available online at: https://www.panafrican-med-journal.com//content/article/39/134/full

Clinical characteristics and outcomes for pregnant women diagnosed with COVID-19 disease at the University of Benin Teaching Hospital, Benin City, Nigeria

James Osaikhuwuomwan¹, Michael Ezeanochie¹, Charles Uwagboe¹, Kingsley Ndukwu¹, Sofiat Yusuf¹, Adedapo Ande¹,², &¹Department of Obstetrics and Gynaecology, University of Benin Teaching Hospital, Benin City, Edo State, Nigeria, ²Materno-Foetal Unit, University of Benin Teaching Hospital, Benin City, Edo State, Nigeria
Introduction

The coronavirus disease (COVID-19) pandemic has challenged health systems around the world. The disease is caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection [1]. It is a novel respiratory disease that is highly infectious and may lead to multiple organ failure and death [1]. The emergence and rapid spread of the new coronavirus across the world poses severe threat to global public health [1,2].

Symptoms that may be associated with COVID-19 disease include fever, dry cough, sore throat, malaise, loss of sense of taste and smell, shortness of breath and respiratory distress [2,3]. Measures such as physical distancing, movement restrictions and “lock downs” were instituted by various countries to curb the rapid spread of the disease [4,5]. These interventions had implications for routine healthcare services which suffered disruptions as health systems struggled to cope with the effects of the pandemic. Furthermore, while data from previous coronavirus outbreaks documented pregnancy as a risk factor for worse outcomes, early reports from COVID-19 infection in pregnancy appear to be different [6]. While studies have associated COVID-19 infection in pregnancy with increased risk of miscarriage, foetal growth restriction, and preterm birth [7-9], other published results have not observed any significant effects of the disease on obstetric and neonatal outcome [10,11].

A recent systematic review with meta-analysis noted that while previous coronavirus outbreaks (Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS)) have associated infections during pregnancy with more serious illness, the maternal morbidity for COVID-19 infection during pregnancy appears like that of non-pregnant women of reproductive age [10,11]. It recommends the need for more evidence to sufficiently address the relationship between COVID-19, pregnancy, and the effects on maternal and neonatal outcomes. The maternity unit of the University of Benin Teaching Hospital,
Benin City is a major referral obstetric unit in Southern Nigeria. It continued to render obstetric services during the pandemic and was also designated as a centre to manage patients with COVID-19 infection during pregnancy. This study was conducted to document our experience with the management of pregnant women with COVID-19 infection during pregnancy. It explores the socio-demographic characteristics of the women, clinical features at presentation, the associated comorbidities and maternal-foetal pregnancy outcomes. This will add to the literature; existing-cum-emerging scientific information on this novel coronavirus infection and contribute to improving the quality of care provided to pregnant women affected with the infection.

Methods

Study setting: the University of Benin Teaching Hospital is a major referral tertiary hospital in Southern Nigeria and is one of the designated hospitals for the management of COVID-19 disease in Edo State, Nigeria. The Department of Obstetrics records about 2,600 deliveries annually and continued to provide maternal healthcare services to pregnant women during the pandemic. Services were provided in line with the periodically updated guidelines and protocols from the Nigerian Centre for Disease Control. Patient selection for testing, sample collection, processing, and laboratory testing also followed guidance from Nigeria Centre for Disease Control (NCDC) on COVID-19. All suspected patients had laboratory test for COVID-19 infection via nasopharyngeal or throat swab test for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by using quantitative reverse transcription polymerase chain reaction (qPT-PCR). Positive cases were either admitted to the isolation ward for inpatient care or managed from home on supervised self-isolation based on the NCDC guidelines. Additionally, suspected or confirmed cases in labour were managed in specially designated delivery suites specified for that purpose within the labour ward complex.

Ethical approval for this study was obtained from the UBTH Health and Research Ethics Committee.

Study design and patients: this was a descriptive observational study of all suspected cases of COVID-19 infection that tested positive during the study period from April to September 2020. We retrospectively reviewed the clinical features and outcomes of all pregnant women with COVID-19 infection. Obstetric cases flagged as suspected COVID-19 cases were tested during the study period. The cases that were confirmed COVID-19 positive constitute the study population.

Data analysis: clinical information for the COVID-19 positive patients were collated for analysis. The variables of interest were their socio-demographic and clinical characteristics, laboratory tests results and outcome of treatment (recovery and discharge or death). For those who had delivered, information on pregnancy and neonatal outcomes were retrieved. Data was obtained from the case records, labour ward records, labour ward theatre records and the postnatal ward. The data was analysed using the SPSS software (v.20.0, IBM SPSS). The results are presented as frequency tables with percentages and proportions. Student’s test was performed to compare continuous variables while Chi-square test and Fisher’s exact test were used to compare categorical variables. Statistical significance was set at p value < 0.05.

Results

Overall, there were 67 obstetric patients with suspected COVID-19 symptoms for which nasopharyngeal samples for RTPCR for SARS-CoV-2 nucleic acid were taken. Out of these number, 19 (28.4%) were confirmed with COVID-19 infection. In terms of treatment outcome, 11 women (57.9%) delivered while 7 (36.8%) recovered and were discharged (pregnancy on-going), and 1 (5.3%) maternal death was recorded. Two women (10.5%) had preterm delivery. In Table 1, the clinical profile of the study population is presented. The mean age of the positive cases was 31.4 years (ranged from 22-39) and most (52.6%) were within 31-35 years.
The clinical manifestation of the women is described in Table 2. The common presenting complaints were fever 13/19 (68.4 %) and cough 11/19 (57.9 %). Other clinical symptoms observed were sore throat 31.6% (6/19), malaise 42.1% (8/19), loss of taste, 26.3% (5/19), anosmia 21.1% (4/19), difficulty with breathing 10.55% (2/19). The most common diagnosed co-existing morbidity was hypertensive disorder in pregnancy 26.3% (5/19) while 13 (68.4%) were in the third trimester of pregnancy. In Table 3, the maternal and foetal treatment outcome is presented. Five (26.3%) women received oxygen supplementation while 1(5.3%) required intensive care unit (ICU) admission. Out of the 11 women who delivered, 5 (45.4%) had vaginal delivery and 6 (54.6 %) Caesarean section; 4 (36.4%) emergency and 2 (18.2 %) elective Caesarean sections. The mean birth weight was 3.1kg (ranged from 1.2-4.2) and most of the neonates 9 (81.8%) had normal Apgar scores at birth. Two neonates (18.2%) were admitted into the neonatal unit for birth asphyxia and 1 suffered early neonatal death within 24 hours of birth. In Table 4, the relationship between disease severity (requirement for respiratory support) and presence of co-morbidities in pregnancy was compared. There was a statistically significant difference in the occurrence of severe COVID-19 infection among women who had comorbidities in pregnancy (P = 0.028).

Discussion

In our study, the test positivity rate for COVID-19 infection was high at 28.4%. In addition, majority of our patients had post-secondary education and were diagnosed in pregnancy during the antenatal period. The common presenting symptoms were fever, cough, malaise, sore throat, loss of taste and sense of smell. Hypertensive disease in pregnancy was the commonest diagnosed co-morbid condition and majority of the patients made satisfactory recovery from the infection. Severe COVID-19 requiring oxygen supplementation was significantly more associated with those who had coexisting morbidities at diagnosis. The World Health Organisation (WHO) advises that the test positivity rate should be less than 5% before Governments should consider the COVID-19 infection to be under control for reopening from “lockdown”. The 28.4% recorded in our result is much higher than this recommendation. It may be due to a high prevalence of COVID-19 in the community or a policy of ‘restricted access to COVID-19 testing’. At the time of our study, testing for COVID-19 was restricted only to persons with a history of travel to a place of high disease prevalence and those manifesting symptoms of the infection. A high test positivity has been suggested to indicate that the Government is only testing the sickest patients who seek medical attention and is not casting a wide enough net to know how much of the virus is spreading within its communities [12].

The clinical symptoms of fever, cough, malaise, sore throat, loss of the senses of taste and smell in our study are similar to other published reports on COVID-19 symptoms [8,13]. Furthermore, majority of our patients did not have severe disease requiring respiratory support. In a study conducted in Wuhan, China all pregnant women confirmed with COVID-19 had mild or asymptomatic disease, with fever and cough being the chief symptoms [14]. The proportion of women with severe illness requiring oxygen supplementation is similar to other studies on COVID-19 infection in pregnancy [13]. These suggest that the majority of cases of COVID-19 infections during pregnancy are asymptomatic or mild disease and may not require critical care. In this study, majority of the patients recovered satisfactorily from the infection and were discharged. Eleven were subsequently delivered either via the vaginal route or by Caesarean section for obstetric indications. This suggests that pregnant women with COVID-19 infection respond satisfactorily to standard
supportive therapy and can safely deliver by the vaginal route in well selected cases. This is consistent with the findings of other studies that pregnancy did not confer additional risk for adverse outcome [10,11]. The maternal death recorded was referred from a peripheral hospital with features of puerperal sepsicaemia and multi-organ dysfunction 4 days after an emergency Caesarean section for obstructed labour. She died in the intensive care unit after 3 days on admission.

Majority of the newborns had normal Apgar scores and were not admitted into the neonatal unit. In addition, COVID-19 testing at 48 hours after delivery were negative for all the babies. The only perinatal death recorded in our study was a preterm delivery by emergency Caesarean section at 32 weeks in a woman referred for imminent eclampsia. The neonate, who weighed 1.2 kg died from complications of prematurity, intrauterine growth restriction and respiratory distress syndrome within 24 hours of delivery. Similar studies on foetal outcome among those delivered while diagnosed with COVID-19 infection reported that the disease did not appear to worsen perinatal outcome [15,16]. Although early perinatal COVID-19 infection suggestive of vertical transmission has been described, this was not foundin our study [15,16].

There was a significant association between COVID-19 positive women who developed severe disease requiring respiratory support either by oxygen supplementation or mechanical ventilation and the presence of hypertensive diseases of pregnancy (pre-eclampsia), a co-morbidity. Consistent with our report, Liu et al. [17] reported that adverse pregnancy outcomes was high, especially among those with other co-morbidities such as pre-eclampsia or other complications because respiratory syndromes may aggravate pulmonary oedema and decrease oxygen saturation. The endothelial dysfunction associated with pre-eclampsia predisposes patients to respiratory failure from pulmonary oedema. Also, COVID-19 is primarily a respiratory infection that affects the lungs. The coexistence of the two conditions may have resulted in the rapid deterioration of respiration function among the women. Our study has some limitations. The sample size is comparatively small and we did not compare our variables with those of pregnant women who did not have COVID-19. In addition, we used only negative nasal or throat swab RT-PCR test in the neonates to exclude vertical transmission. The histopathological evaluation of the placenta may have provided relevant additional information.

We consider our results remain valid despite these limitations because the disease is novel with limited published scientific information on various aspects of the infection, especially from sub-Saharan Africa. There is need for further adequately powered studies to evaluate the relationship between COVID-19 in pregnancy and neonatal outcomes.

**Conclusion**

In conclusion, the common presenting clinical symptoms of COVID-19 infection in pregnancy are similar to what has been reported in the non-pregnant population and majority had mild disease. The infection did not appear to worsen the maternal or perinatal outcome of pregnancy. Pre-eclampsia is a common comorbidity associated with COVID-19 in pregnancy and it appears to increase the need for respiratory support. This information is useful for decision making at the point of care when managing women with COVID-19 in infection in pregnancy.

**What is known about this topic**
- COVID-19 infection can affect pregnant women;
- Its effect on pregnancy and its outcome compared to non-pregnant women is still unclear.

**What this study adds**
- COVID-19 infection during pregnancy in a cohort of black African women produces symptoms similar to those seen in non-pregnant adults;
- The occurrence of pre-eclampsia with COVID-19 infection during pregnancy is...
significantly associated with severe disease requiring respiratory support.

Competing interests

The authors declare no competing interests.

Authors’ contributions

The contributions to the work and write-up of the manuscript by each person listed as author: Dr. James Osaikhuwuomwan was jointly responsible for conceptualization of the research, developing research design and data collection instruments, interpreting the results and drafting the final manuscript; Dr. Michael Ezeanochie was jointly responsible for conceptualization of the research, developing research design and data collection instruments, interpreting the results and drafting the final manuscript; Dr. Charles Uwagboe was jointly responsible for data collection, analysis and contributed to the final manuscript; Dr. Kingsley Ndukwu was jointly responsible for data collection, analysis and contributed to the final manuscript; Dr. Sofiat Yusuf was jointly responsible for data collection, analysis and contributed to the final manuscript; Prof. Adedapo Ande provided leadership for the research. He was also responsible for conceptualization of the research, developing research design and data collection instruments, interpreting the results and drafting the final manuscript. All the authors have read and agreed to the final manuscript.

Acknowledgments

The authors wish to acknowledge members of the health team at the University of Benin Teaching Hospital who managed the patients with COVID-19 infection.

Tables

Table 1: clinical profile of COVID-19 positive women
Table 2: common clinical manifestations
Table 3: maternal and foetal treatment outcome

Table 4: association between disease severity and detected comorbidities of pregnancy

References

1. World Health Organization. Naming the coronavirus disease (COVID-19) and the virus that causes it. Accessed 11 February 2020.
2. Schwartz DA. An analysis of 38 pregnant women with COVID-19, their newborn infants, and maternal-fetal transmission of SARS-CoV-2: maternal coronavirus infections and pregnancy outcomes. Arch Pathol Lab Med. 2020 Jul 1;144(7): 799-805. PubMed | Google Scholar
3. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance. 2020;28. PubMed | Google Scholar
4. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China (Chinese). Chinese Center for Disease Control and Prevention Weekly. 2020 Feb 10;41(2): 145-151. PubMed | Google Scholar
5. NCDC interim guidance. Infection prevention and control recommendations during health care provision for suspected and confirmed cases of COVID-19. NCDC interim guidance. 2020. PubMed | Google Scholar
6. Khalil A, Kalafat E, Benlioglu C, O’Brien P, Morris E, Draycott T et al. SARS-CoV-2 infection in pregnancy: a systematic review and meta-analysis of clinical features and pregnancy outcomes. EClinicalMedicine. 2020;25: 100446. PubMed | Google Scholar
7. Schwartz DA, Graham AL. Potential maternal and infant outcomes from (Wuhan) coronavirus 2019-nCoV infecting pregnant women: lessons from SARS, MERS, and other human coronavirus infections. Viruses. 2020 Feb 10;12(2): 194. PubMed | Google Scholar
8. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020 Mar 7;395(10226): 809-815. PubMed | Google Scholar

9. Qiao J. What are the risks of COVID-19 infection in pregnant women. Lancet. 2020 Mar 7;395(10226): 760-762. PubMed | Google Scholar

10. Di Mascio D, Khalil A, Saccone G, Rizzo G, Buca D, Liberati M et al. Outcome of Coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and metaanalysis. Am J Obstet Gynecol MFM. 2020 May;2(2): 100107. PubMed | Google Scholar

11. Lamouroux A, Attie-Bitach T, Martinovic J, Leruez-Ville M, Ville Y. Evidence for and against vertical transmission for SARS-CoV-2 (COVID-19). Am J Obstet Gynecol. 2020 Jul;223(1): 91.e1-91.e4. PubMed | Google Scholar

12. Johns Hopkins University and Medicine. Coronavirus Resource Centre. Accessed 20 December, 2020.

13. Adhikari H, Moreno W, Zofkie A, MacDonald L, McIntire D, Collins R et al. Pregnancy outcomes among women with and without severe acute respiratory syndrome coronavirus 2 Infection. JAMA Netw Open. 2020;3(11): e2029256. PubMed | Google Scholar

14. Hui Y, Guoqiang S, Fei T, Min P, Ying G, Jing P et al. Clinical features and outcomes of pregnant women suspected of coronavirus disease 2019. J Infection. 2020;81: e40-44. Google Scholar

15. Ayed A, Embaireeg A, Benawadh A, Al-Fouzan W, Hammoud M, Al-Hathal M et al. Maternal and perinatal characteristics and outcomes of pregnancies complicated with COVID-19 in Kuwait. BMC Pregnancy Childbirth. 2020; 2;20(1): 754. PubMed | Google Scholar

16. Yee J, Kim W, Han JM, Yoon HY, Lee N, Lee KE et al. Clinical manifestations and perinatal outcomes of pregnant women with COVID-19: a systematic review and meta-analysis. Sci Rep. 2020 Oct 22;10(1): 18126. PubMed | Google Scholar

17. Liu H, Liu F, Li J, Zhang T, Wang D, Lan W. Clinical and CT imaging features of the COVID-19 pneumonia: focus on pregnant women and children. J Infect. 2020 May;80(5): e7-e13. PubMed | Google Scholar
### Table 1: clinical profile of COVID-19 positive women

| Variable                                      | Number (%)       |
|-----------------------------------------------|------------------|
| Age: mean ± SD (years)                        | 31.4 ± 4.1       |
| Age interval (years)                          |                  |
| 21-25                                         | 1 (5.3)          |
| 26-30                                         | 5 (26.3)         |
| 31-35                                         | 10 (52.6)        |
| 36-40                                         | 3 (15.8)         |
| Parity:                                       |                  |
| Para 0                                        | 5 (26.3)         |
| Para 1-4                                      | 12 (63.2)        |
| Para ≥ 5                                      | 2 (10.5)         |
| Education                                     |                  |
| Primary                                       | 1 (5.3)          |
| Secondary post-secondary (tertiary)           | 3 (15.8) 15 (78.9) |
| Period at diagnosis                           |                  |
| Antenatal                                     | 15 (78.9)        |
| Intrapartum                                   | 2 (10.5)         |
| Postpartum                                    | 2 (10.5)         |
| Gestational age (weeks)                       |                  |
| Mean (SD)                                     | 30.4 (7.7)       |
| Range                                         | 12-40            |
| Trimester of pregnancy (at diagnosis)         |                  |
| First                                         | 1 (5.3)          |
| Second                                        | 5 (26.3)         |
| Third                                         | 13 (68.4)        |

### Table 2: common clinical manifestations

| Variable                                      | N (%)            |
|-----------------------------------------------|------------------|
| Fever                                         | 13 (68.4)        |
| Cough                                         | 11 (57.9)        |
| Sore throat                                   | 6 (31.6)         |
| Malaise                                       | 8 (42.1)         |
| Anosmia                                       | 4 (21.1)         |
| Loss of smell                                 | 5 (26.3)         |
| Difficult breathing                           | 3 (15.8)         |
| Asymptomatic                                  | 2 (10.5)         |
| Associated co-morbidities*:                   |                  |
| Preeclampsia/eclampsia                        | 5 (26.3)         |
| Retroviral disease                            | 1 (5.3)          |
| Acute pyelonephritis                          | 1 (5.3)          |
| Preterm premature rupture of membranes (PROM) | 2 (10.5)         |
| Pelviper sepsis                               | 1 (5.3)          |

*Some patients had multiple co-morbidities
### Table 3: maternal and foetal treatment outcome

| Variable                          | Number (%) |
|-----------------------------------|------------|
| **Treatment**                     |            |
| Inpatient care                    | 10 (52.6)  |
| Outpatient care                   | 9 (47.4)   |
| Used oxygen                       | 5 (26.3)   |
| ICU admission                     | 1 (5.3)    |
| **Obstetric outcome**             |            |
| Full recovery and delivered       | 11 (57.9)  |
| Full recovery ongoing pregnancy   | 7 (36.8)   |
| Maternal death                    | 1 (5.3)    |
| **Mode of delivery**              |            |
| Vaginal delivery                  | 5 (26.3)   |
| Caesarean section                 | 6 (31.6)   |
| **Birth weight (kg):**            |            |
| Mean ± SD                         | 3.1 ± 0.8  |
| Range                             | 1.2-4.2    |
| **Birth asphyxia**                |            |
| None                              | 9 (81.8)   |
| Mild                              | 1 (9.1)    |
| Moderate                          | 1 (9.1)    |
| Severe                            | 0 (0)      |
| **Admission into neonatal unit**  |            |
| 2 (10.5)                          |
| **COVID-19 positive neonate**     | 0 (0)      |
| **Early neonatal death**          | 1 (5.3)    |

### Table 4: association between disease severity and detected comorbidities of pregnancy

| Variable                  | Severe disease used oxygen n = 5 | Mild disease no oxygen n = 14 | Test statistics | P-value |
|---------------------------|----------------------------------|-------------------------------|-----------------|---------|
| Obstetric co-morbidity    |                                  |                               |                 |         |
| None                      | 1                                | 11                            |                 |         |
| Preeclampsia/eclampsia    | 3                                | 2                             | 10.835          | 0.028   |
| Acute pyelonephritis      | 0                                | 1                             |                 |         |
| Puerperal sepsis          | 1                                | 0                             |                 |         |